Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904896 | 0.93 | NPBWR1 (0.47) | ADORA2BADORA1ADORA2ANPBWR1CMA1 | |
| SCHEMBL4908302 | 0.93 | ADORA2B (0.45) | ADORA2BADORA1ADORA2ATDP1ADORA3 | |
| SCHEMBL4867838 | 0.91 | ADORA2B (0.40) | ADORA2BADORA1ADORA2AGABRA5ADORA3 | |
| SCHEMBL4897242 | 0.90 | ADORA2B (0.42) | ADORA2BADORA1ADORA2ATDP1ADORA3 | |
| SCHEMBL4889396 | 0.89 | ADORA2B (0.43) | ADORA2BADORA1ADORA2ANPBWR1CMA1 | |
| SCHEMBL4791799 | 0.88 | NPBWR1 (0.40) | ADORA2BADORA1ADORA2ANPBWR1CMA1 | |
| SCHEMBL4791802 | 0.88 | NPBWR1 (0.40) | ADORA2BADORA1ADORA2ANPBWR1CMA1 | |
| SCHEMBL4889399 | 0.84 | NPBWR1 (0.41) | ADORA2BADORA1ADORA2ANPBWR1CMA1 | |
| SCHEMBL4866971 | 0.83 | ADORA2B (0.44) | ADORA2BADORA1ADORA2AGABRA5TDP1 | |
| SCHEMBL4866686 | 0.82 | MAPT (0.44) | ADORA2BADORA1ADORA2AGABRA5DCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 4/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.